ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
133.197,57
0,14%
S&P 500
5.742,75
-0,05%
US Dollar vs BRL
5,4414
0,06%
Bitcoin
66.249,75
1,64%
Brent Oil
71,525
0,81%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Europa
  5. EU
  6. Transgene SA (TNG)

  7. Transgene SA (TNG) Notícias

TNG

Transgene (TNG)

Transgene SA
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:EU:TNG
DataHoraFonteTítuloCódigoCompanhia
24/09/202412:45GlobeNewswire Inc.Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025EU:TNGTransgene SA
14/09/202404:05GlobeNewswire Inc.Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous TreatmentsEU:TNGTransgene SA
10/09/202402:30GlobeNewswire Inc.Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of InnovationEU:TNGTransgene SA
09/09/202402:00GlobeNewswire Inc.Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024EU:TNGTransgene SA
05/09/202412:45GlobeNewswire Inc.Transgene to Participate in HTID Conference and Investor Access Forum in ParisEU:TNGTransgene SA
27/08/202402:30GlobeNewswire Inc.Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITCEU:TNGTransgene SA
22/07/202403:00GlobeNewswire Inc.Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024EU:TNGTransgene SA
03/06/202402:30GlobeNewswire Inc.Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck CancerEU:TNGTransgene SA
03/06/202402:30GlobeNewswire Inc.Transgene – Premier patient inclus dans la partie Phase II de l’étude randomisée de Phase I/II de son actif phare TG4050, un vaccin thérapeutique individualisé évalué dans les cancers de la tête et du couEU:TNGTransgene SA
15/05/202412:45GlobeNewswire Inc.Assemblée Générale Mixte de Transgene du 15 mai 2024EU:TNGTransgene SA
15/05/202412:45GlobeNewswire Inc.Transgene’s Combined General Meeting of May 15, 2024EU:TNGTransgene SA
14/05/202412:45GlobeNewswire Inc.Transgene provides business and financial update for Q1 2024EU:TNGTransgene SA
14/05/202412:45GlobeNewswire Inc.Transgene fait le point sur ses activités et sa situation financière au premier trimestre 2024EU:TNGTransgene SA
24/04/202412:45GlobeNewswire Inc.Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai 2024EU:TNGTransgene SA
24/04/202412:45GlobeNewswire Inc.Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024EU:TNGTransgene SA
11/04/202414:05GlobeNewswire Inc.Document d'enregistrement Universel 2023EU:TNGTransgene SA
11/04/202412:45GlobeNewswire Inc.MIse à disposition du document d'enregistrement universel 2023 de TransgeneEU:TNGTransgene SA
11/04/202412:45GlobeNewswire Inc.Availability of Transgene's 2023 Universal Registration DocumentEU:TNGTransgene SA
09/04/202412:45GlobeNewswire Inc.Transgene et NEC présentent les premiers signes de bénéfice clinique de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à l’AACR 2024EU:TNGTransgene SA
09/04/202412:45GlobeNewswire Inc.Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024EU:TNGTransgene SA
27/03/202413:45GlobeNewswire Inc.Transgene prévoit des avancées significatives sur son portefeuille d’immunothérapies en 2024 et étend sa visibilité financière jusqu’au 4ème trimestre 2025EU:TNGTransgene SA
27/03/202413:45GlobeNewswire Inc.Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025EU:TNGTransgene SA
27/03/202413:45GlobeNewswire Inc.Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources OfficerEU:TNGTransgene SA
27/03/202413:45GlobeNewswire Inc.Transgene nomme Lucie Larguier en tant que Directrice Financière et Christelle Schwoerer Comme Directrice des Ressources HumainesEU:TNGTransgene SA
18/03/202413:45GlobeNewswire Inc.Transgene annonce ses prochaines rencontres avec les investisseursEU:TNGTransgene SA
18/03/202413:45GlobeNewswire Inc.Transgene Announces Upcoming Investor MeetingsEU:TNGTransgene SA
06/03/202403:30GlobeNewswire Inc.Transgene présentera de nouvelles données sur son vaccin individualisé TG4050 à l’AACR 2024EU:TNGTransgene SA
06/03/202403:30GlobeNewswire Inc.Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024EU:TNGTransgene SA
05/03/202403:30GlobeNewswire Inc.Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050EU:TNGTransgene SA
05/03/202403:30GlobeNewswire Inc.Transgene, NEC et BostonGene étendent leur collaboration dans le cadre de l’essai clinique de Phase I/II du vaccin individualisé TG4050EU:TNGTransgene SA
 Apresentando as notícias mais relevantes sobre:EU:TNG

Seu Histórico Recente

NASDAQ
AAYYYXX
Goldman Sachs Bank Usa P...
LSE
58YS
Newday 26 A
NASDAQ
FRHSTX
Megacap Portfolio Series...
COIN
DTHBTC
LSE
HH62
Citi Fun 28
TG
R2FA
Greenwing Resources
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados